Kejin Biopharma-B (2595) narrowed its interim loss to RMB 220 million from RMB 698 million a year earlier, while revenue fell 52% to RMB 42.473 million, according to Ming Pao.
The company said it will not pay a dividend.
記事
Kejin Biopharma Narrows Interim Loss To RMB 220 Million
--・